AU776955B2 - Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin - Google Patents

Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin Download PDF

Info

Publication number
AU776955B2
AU776955B2 AU31454/00A AU3145400A AU776955B2 AU 776955 B2 AU776955 B2 AU 776955B2 AU 31454/00 A AU31454/00 A AU 31454/00A AU 3145400 A AU3145400 A AU 3145400A AU 776955 B2 AU776955 B2 AU 776955B2
Authority
AU
Australia
Prior art keywords
tissue
viruses
virus
hmgi
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU31454/00A
Other languages
English (en)
Other versions
AU3145400A (en
Inventor
Jorn Bullerdiek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19904514A external-priority patent/DE19904514A1/de
Priority claimed from DE19943787A external-priority patent/DE19943787A1/de
Priority claimed from DE19943786A external-priority patent/DE19943786A1/de
Application filed by Individual filed Critical Individual
Publication of AU3145400A publication Critical patent/AU3145400A/en
Application granted granted Critical
Publication of AU776955B2 publication Critical patent/AU776955B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU31454/00A 1999-02-04 2000-02-04 Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin Ceased AU776955B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DE19904514A DE19904514A1 (de) 1999-02-04 1999-02-04 Mittel zur Prävention und/oder Behandlung von Leiomyomen
DE19904514 1999-02-04
DE19943787A DE19943787A1 (de) 1999-09-13 1999-09-13 Mittel zur Prävention und/oder Behandlung von Gewebeveränderungen mesenchymalen Ursprungs
DE19943786 1999-09-13
DE19943786A DE19943786A1 (de) 1999-09-13 1999-09-13 Mittel zur Prävention und/oder Behandlung von Gewebeveränderungen mesenchymalen Ursprungs
DE19943787 1999-09-13
PCT/DE2000/000364 WO2000045851A2 (de) 1999-02-04 2000-02-04 Mittel zur prävention und/oder behandlung einer gewebeveränderung mesenchymalen ursprungs

Publications (2)

Publication Number Publication Date
AU3145400A AU3145400A (en) 2000-08-25
AU776955B2 true AU776955B2 (en) 2004-09-30

Family

ID=27218954

Family Applications (1)

Application Number Title Priority Date Filing Date
AU31454/00A Ceased AU776955B2 (en) 1999-02-04 2000-02-04 Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin

Country Status (8)

Country Link
US (2) US20070202115A1 (cg-RX-API-DMAC10.html)
EP (1) EP1146881B1 (cg-RX-API-DMAC10.html)
JP (1) JP2002536345A (cg-RX-API-DMAC10.html)
AT (1) ATE314854T1 (cg-RX-API-DMAC10.html)
AU (1) AU776955B2 (cg-RX-API-DMAC10.html)
CA (1) CA2360942A1 (cg-RX-API-DMAC10.html)
DE (2) DE50012015D1 (cg-RX-API-DMAC10.html)
WO (1) WO2000045851A2 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722411B2 (en) 2009-10-07 2014-05-13 The State Of Israel, Ministry Of Agriculture & Rural Development, Kimron Veterinary Institute Brucella phage polynucleotides and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998021201A1 (en) * 1996-11-14 1998-05-22 Takeda Chemical Industries, Ltd. Crystals of benzimidazole derivatives and their production

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016629A2 (en) * 1994-11-18 1996-06-06 Amira Inc Phosphinic creatine compounds having antiviral activity
US5972666A (en) * 1996-07-26 1999-10-26 G. D. Searle & Co. Assembly-deficient herpesvirus vaccine
GB9623522D0 (en) * 1996-11-11 1997-01-08 Pharmacia & Upjohn Spa Benzoheterocycle distamycin derivatives process for preparing them and their use as antitumour and antiviral agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998021201A1 (en) * 1996-11-14 1998-05-22 Takeda Chemical Industries, Ltd. Crystals of benzimidazole derivatives and their production

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CORDERO F ET AL, AIDS 11(14) P 1787-8 *
REYEZI JA ET AL, ORAL SURG. OR MED. OR PATHOL. 81(1) 55-62 *

Also Published As

Publication number Publication date
US20070202115A1 (en) 2007-08-30
JP2002536345A (ja) 2002-10-29
EP1146881A2 (de) 2001-10-24
EP1146881B1 (de) 2006-01-04
US20090304708A1 (en) 2009-12-10
AU3145400A (en) 2000-08-25
ATE314854T1 (de) 2006-02-15
WO2000045851A3 (de) 2000-12-28
DE10080190D2 (de) 2002-01-24
CA2360942A1 (en) 2000-08-10
WO2000045851A2 (de) 2000-08-10
DE50012015D1 (de) 2006-03-30

Similar Documents

Publication Publication Date Title
CN101448848B (zh) Ras突变及其相关组合物和方法
DK2081586T3 (en) RSPONDINES AS MODULATORS OF ANGIOGENESE AND VASCULOGENESES
KR100355111B1 (ko) 발췌제거cDNA라이브러리제조법및제조된라이브러리의용도
KR20040072626A (ko) 혈액학적 악성종양의 검출, 진단 및 치료용 조성물 및 방법
JP2007502612A (ja) コロナウイルス、核酸、蛋白質、ならびにワクチンの生成方法、薬剤および診断
MX2010008168A (es) Biomarcadores p53.
JP2009100768A (ja) 腫瘍形成形質転換に関連する内因性レトロウイルスポリペプチド
US6322794B1 (en) Seroreactive epitopes on proteins of human papillomavirus (HPV) 18
KR100204258B1 (ko) 재조합 고양이 코로나바이러스 에스 단백질
CN1643148B (zh) 小鼠精子形成基因、人男性不育关连基因、以及利用该基因的诊断系统
KR20140134923A (ko) Tgfbi를 이용한 패혈증 진단용 조성물 및 이를 이용한 패혈증 예방 또는 치료용 약학적 조성물과 이의 스크리닝 방법
WO2010011952A2 (en) Highly potent peptides to control cancer and neurodegenerative diseases
JPH09510346A (ja) 哺乳動物細胞における新生物形質転換の制御に関連する遺伝子および遺伝学的因子
AU2002233299B2 (en) Method for modulating the binding activity of a novel ICAM-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes
US20130316958A1 (en) Highly potent peptides to control cancer and neurodegenerative diseases
JPH11514864A (ja) ヘルペスウイルスのrfhv/kshv亜科の糖タンパク質b
CN113384700A (zh) 一种能有效抑制埃博拉病毒感染的靶点ly6e及其应用
Atreya et al. The rubella virus putative replicase interacts with the retinoblastoma tumor suppressor protein
EA009782B1 (ru) Пептид, происходящий из вируса гепатита с
US20090304708A1 (en) Preparation for the Prevention and/or Treatment of a Tissue Change of Mesenchymal Origin
WO2000014263A9 (en) Recombinant hepatitis a virus (hav), hav variants, hav-based vaccines and methods of producing them
US6569616B1 (en) Human cytomegalovirus glycoprotein O as a new drug target and subunit vaccine candidate
JP7764502B2 (ja) 環状RNA Circ-ACE2翻訳によるポリペプチド及びその使用
Wang et al. GB virus type C E2 protein inhibits human immunodeficiency virus type 1 gag assembly by downregulating human ADP-ribosylation factor 1
CN111808938A (zh) Atp6v0d2用于动脉粥样硬化的早期诊断或疗效监控